WASHINGTON - As biotech emerges from the wreckage of what G. Steven Burrill calls the "Sam and Martha sideshow," and as uncertainties over war in Iraq, the new requirements of financial reporting and devalued market capitalizations continue to plaque the industry, there is only one direction left for the industry to go: up. Read More